查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1426136

全球 ACE 抑制劑市場，依藥物、給藥途徑、適應症、最終使用者、地區、機會、預測，2017-2031 年

ACE Inhibitors Market Assessment, Drugs, By Route of Administration, By Indication, By End-user, By Region, Opportunities and Forecast, 2017-2031F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 228 Pages | 商品交期: 3-5個工作天內

價格

2023年全球ACE抑制劑市場規模達71.6億美元。 預計到 2031 年，市場規模將達到 108.6 億美元，2024-2031 年預測期間複合年增長率為 5.34%。 全球ACE抑制劑市場受到多種因素的推動，包括高血壓等心血管疾病盛行率的上升，導致對具有成本效益的藥物的需求增加。 高血壓治療的創新新產品的推出是推動市場成長的主要因素。 此外，人們對 ACE 抑制劑在治療各種心血管疾病方面的益處的認識不斷提高、藥物配方的進步以及旨在提高 ACE 抑制劑的功效和安全性的研發活動等因素也在推動市場發展。 。

ACE抑制劑對於預防心臟病患者的死亡和促進健康非常有益。 主要市場參與者開拓新藥以及提高患者對心電圖等定期檢查的認識正在推動全球血管緊張素轉換□抑制劑市場的成長。 此外，政府措施預計將改善發展中國家和欠發達國家獲得篩選技術和高效藥物開發的機會，從而增加這些市場獲得 ACE 抑制劑的機會。

由於全球心血管疾病的增加，對 ACE 抑制劑的需求迅速增加。 ACE抑制劑在透過放鬆靜脈和動脈來降低血壓方面發揮著重要作用。 因此，ACE抑制劑是預防危及生命的心臟病的重要藥物。 根據美國心臟協會的數據，2020 年約有 1,910 萬人死於心血管疾病。 缺血性心臟病影響全球約 2.441 億人。 ACE抑制劑在控制血壓、冠狀動脈疾病、預防心臟衰竭和心臟病方面非常有效。 由於人們對 ACE 抑制劑的益處和潛力的認識不斷提高，全球對 ACE 抑制劑的需求不斷增加。

本報告調查了全球 ACE 抑制劑市場，並提供了市場概況，包括藥物趨勢、給藥途徑、適應症、最終用戶、地區以及進入市場的公司概況。

目錄

第1章研究方法

第 2 章專案範圍與定義

第 3 章執行摘要

第 4 章 2017-2031 年全球 ACE 抑制劑市場前景

  • 市場規模與預測
  • 透過藥物
  • 依給藥途徑
  • 依指示
  • 按最終用戶
  • 按地區
  • 各公司的市佔率 (%)，2023 年

第 5 章 2017-2031 年全球 ACE 抑制劑市場前景（按地區）

  • 北美
  • 歐洲
  • 南美洲
  • 亞太地區
  • 中東/非洲

第 6 章市場地圖，2023 年

第7章宏觀環境與產業結構

  • 需求與供給分析
  • 匯入/匯出分析
  • 價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第 8 章市場動態

第 9 章監理架構與創新

第10章主要參會企業狀況

第11章價格分析

第 12 章案例研究

第13章主要公司展望

  • Novartis AG
  • Pfizer Inc.
  • AstraZeneca Plc.
  • Sanofi Winthrop Industries
  • Boehringer Ingelheim International GmbH
  • Merck & Co., Inc.
  • Lupin Pharmaceutical, Inc.
  • Sun Pharmaceutical Industries Limited
  • Bayer AG
  • Cipla Limited
  • AbbVie Inc.
  • Bristol-Myers Squibb Pharmaceuticals Limited

第 14 章策略建議

第15章查詢及免責聲明

Product Code: MX10999

Global ACE inhibitors market size was valued at USD 7.16 billion in 2023 and is expected to reach USD 10.86 billion in 2031, with a CAGR of 5.34% for the forecast period between 2024 and 2031. The global ACE inhibitors market is driven by several factors, including the rising prevalence of cardiovascular disorders, such as hypertension, which has increased demand for cost-effective drugs. Introducing new innovative products for treating hypertension is a major factor driving the market growth. Additionally, the market is influenced by factors such as the growing awareness of the benefits of ACE inhibitors in managing various cardiovascular conditions, advancements in drug formulations, and research and development activities aimed at enhancing ACE inhibitors' efficacy and safety profiles.

ACE Inhibitors are highly beneficial in preventing death and promoting health in heart patients. The development of novel drugs by the key market players and rising awareness among patients regarding regular check-ups, such as ECG, are driving the growth of the global ACE inhibitors market. Moreover, governmental initiatives are expected to improve access to screening technologies and efficient drug developments in developing and under-developed countries, which will increase access to ACE inhibitors in these markets.

Increasing Prevalence of Cardiovascular Patients

There has been a surge in demand for ACE Inhibitors due to rising number of cardiovascular diseases worldwide. ACE Inhibitors plays a crucial role in relaxing the veins and arteries to lower the blood pressure. Due to it, the inhibitors act as an important drug in preventing life-threating heart condition. According to American Heart Association, around 19.1 million people died in 2020 due to cardiovascular diseases. Around 244.1 million people were affected by ischemic heart diseases globally. ACE inhibitors are highly efficient in controlling blood pressure and coronary artery diseases and prevents heart failures and heart attack. There is an increased awareness among the people regarding benefits and potential of ACE inhibitors, due to which, there has been a consistent increase in demand for ACE inhibitors globally.

ACE Inhibitors are Receiving Significant Investments from Stakeholders

With high prevalence of cardiovascular diseases, there is a high demand to invest in research and development in the medicines for management of heart diseases. ACE Inhibitors have the potential to control and prevent heart health outcomes such as strokes, ischaemic heart diseases. Due to it, pharmaceuticals companies are continuously investing and launching modern ACE inhibitors.

In February 2023, Travere Therapeutics, Inc. announced FDA approval for Filspari to reduce proteinuria in adults, who are affected by IgAN, which is a rare kidney disease. Filspari is an ACE inhibitor which has proved to be beneficial for the patients suffering from IgAN and have the potential to reduce proteinuria and further prevent kidney failure.

Government Initiatives

As the prevalence of chronic diseases is increasing globally, governments are consistently launching initiatives and policies to improve access to ACE inhibitors in developed and emerging countries. Government support for research and development in the pharmaceutical industry, including the development of ACE inhibitors, is a key factor in driving innovation and market growth. Additionally, regulatory approval process and healthcare policies can impact market dynamics and the availability of ACE inhibitors.

For instance, World Heart Vision 2030 was launched by the World Heart Federation to bring policies and programs to improve cardiovascular health and reduce cardiovascular conditions such as heart failure and heart attack. Several steps were taken under these initiatives, such as increasing awareness regarding therapeutical approaches towards heart health, research and development for efficient drug discoveries, and improved accessibility to heart care facilities.

Rapid Growth in Demand for Lisinopril Drugs

Among the drugs segment, Lisinopril holds a significant share in global ACE inhibitors market. Tremendous research and development activities and increased investments by key market players in the segment are leading to the huge demand for Lisinopril Drugs in the ACE inhibitors market. Moreover, its potential to control blood pressure by widening blood vessels is the main reason behind its increasing demand. Due to this, many key market players are including drugs in their product portfolio. In September 2023, Almatica Pharma LLC., a global leader in developing medicines for several therapy areas such as cardiovascular diseases, psychiatry, and pain management recently received FDA approval for Zestril (lisinopril), specially manufactured for managing hypertension. Supportive regulatory systems are enabling pharmaceutical companies to invest and launch drugs for these heart conditions.

North America Holds the Largest Share in the Market

North America holds the highest share of the global ACE inhibitors market. Robust healthcare infrastructure and advanced healthcare facilities are some of the factors that make North America a global leader in the healthcare market. Growing awareness about the importance and benefits of screening and early diagnosis in preventing heart related diseases is driving the demand for ACE inhibitors globally. Growing focus on preventive healthcare, along with increasing availability of healthcare professionals, further leads to growing usage of ACE inhibitors for reducing the probability of mortality due to cardiovascular disorders. With the growing prevalence of cardiovascular diseases in the USA, there is a huge demand for ACE Inhibitors in the region. For instance, according to CDC, the most common cause of death in the United States is heart disease, and over 805,000 Americans get a heart attack each year. Due to this, the demand for ACE inhibitors is expected to grow in North America.

Future Market Scenario

Global ACE inhibitors market is expected to grow in the coming years, due to multiple factors. Primarily, the increasing elderly population, which is prone to cardiovascular and other chronic diseases. It has further led to increase in demand for ACE Inhibitors to provide treatment. Rising awareness regarding the screening programs, along with increased research and developments are also contributing to the market's growth. Additionally, the market is being influenced by the growing demand for cost-effective drugs and the development of combination therapies such as ACE Inhibitors and diuretics and ACE Inhibitors and angiotensin receptor blockers. Geographically, Asia-Pacific is expected to experience the fastest growth, driven by a sizable population base, rising urbanization, and an increase in the prevalence of cardiovascular diseases.

Key Players Landscape and Outlook

In the ACE inhibitors market, public and private companies are progressively establishing initiatives, strategic partnerships, and distribution agreements, which are pivotal in propelling the global ACE inhibitors market's expansion. These alliances empower firms to adapt to each other's strengths, gain access to new markets and technologies, and pool resources for research and development endeavors. Distribution agreements enable companies to broaden their market presence at an international level.

In January 2023, AstraZeneca acquired CinCor Pharma, Inc., a biopharmaceutical company, working on novel treatments for hypertension as well as chronic kidney disease by developing medicines such as ACE inhibitors. The strategic acquisition will enable the company to enhance its portfolio for the management of cardiovascular diseases, which will further expand the company's global presence.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Executive Summary

4. Global ACE Inhibitors Market Outlook, 2017-2031F

  • 4.1. Market Size & Forecast
    • 4.1.1. Value
    • 4.1.2. Volume
  • 4.2. By Drugs
    • 4.2.1. Lisinopril
    • 4.2.2. Ramipril
    • 4.2.3. Enalapril
    • 4.2.4. Benazepril
    • 4.2.5. Fosinopril
    • 4.2.6. Captopril
    • 4.2.7. Moexipril
    • 4.2.8. Others
  • 4.3. By Route of Administration
    • 4.3.1. Oral
    • 4.3.2. Injectable
  • 4.4. By Indication
    • 4.4.1. Heart Failure
    • 4.4.2. Hypertension
    • 4.4.3. Diabetes
    • 4.4.4. Heart Attack
    • 4.4.5. Chronic Kidney Disease
    • 4.4.6. Others
  • 4.5. By End-user
    • 4.5.1. Retail Pharmacy
    • 4.5.2. Hospital Pharmacy
    • 4.5.3. Online Pharmacy
    • 4.5.4. E-commerce Websites
  • 4.6. By Region
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. South America
    • 4.6.4. Asia-Pacific
    • 4.6.5. Middle East and Africa
  • 4.7. By Company Market Share (%), 2023

5. Global ACE Inhibitors Market Outlook, By Region, 2017-2031F

  • 5.1. North America*
    • 5.1.1. Market Size & Forecast
      • 5.1.1.1. Value
      • 5.1.1.2. Volume
    • 5.1.2. By Drugs
      • 5.1.2.1. Lisinopril
      • 5.1.2.2. Ramipril
      • 5.1.2.3. Enalapril
      • 5.1.2.4. Benazepril
      • 5.1.2.5. Fosinopril
      • 5.1.2.6. Captopril
      • 5.1.2.7. Moexipril
      • 5.1.2.8. Others
    • 5.1.3. By Route of Administration
      • 5.1.3.1. Oral
      • 5.1.3.2. Injectable
    • 5.1.4. By Indication
      • 5.1.4.1. Heart Failure
      • 5.1.4.2. Hypertension
      • 5.1.4.3. Diabetes
      • 5.1.4.4. Heart Attack
      • 5.1.4.5. Chronic Kidney Disease
      • 5.1.4.6. Others
    • 5.1.5. By End-user
      • 5.1.5.1. Retail Pharmacy
      • 5.1.5.2. Hospital Pharmacy
      • 5.1.5.3. Online Pharmacy
      • 5.1.5.4. E-commerce Websites
    • 5.1.6. United States*
      • 5.1.6.1. By Drugs
      • 5.1.6.1.1. Lisinopril
      • 5.1.6.1.2. Ramipril
      • 5.1.6.1.3. Enalapril
      • 5.1.6.1.4. Benazepril
      • 5.1.6.1.5. Fosinopril
      • 5.1.6.1.6. Captopril
      • 5.1.6.1.7. Moexipril
      • 5.1.6.1.8. Others
      • 5.1.6.2. By Route of Administration
      • 5.1.6.2.1. Oral
      • 5.1.6.2.2. Injectable
      • 5.1.6.3. By Indication
      • 5.1.6.3.1. Heart Failure
      • 5.1.6.3.2. Hypertension
      • 5.1.6.3.3. Diabetes
      • 5.1.6.3.4. Heart Attack
      • 5.1.6.3.5. Chronic Kidney Disease
      • 5.1.6.3.6. Others
      • 5.1.6.4. By End-user
      • 5.1.6.4.1. Retail Pharmacy
      • 5.1.6.4.2. Hospital Pharmacy
      • 5.1.6.4.3. Online Pharmacy
      • 5.1.6.4.4. E-commerce Websites
    • 5.1.7. Canada
    • 5.1.8. Mexico

All segments will be provided for all regions and countries covered

  • 5.2. Europe
    • 5.2.1. Germany
    • 5.2.2. France
    • 5.2.3. Italy
    • 5.2.4. United Kingdom
    • 5.2.5. Russia
    • 5.2.6. Netherlands
    • 5.2.7. Spain
    • 5.2.8. Turkey
    • 5.2.9. Poland
  • 5.3. South America
    • 5.3.1. Brazil
    • 5.3.2. Argentina
  • 5.4. Asia Pacific
    • 5.4.1. India
    • 5.4.2. China
    • 5.4.3. Japan
    • 5.4.4. Australia
    • 5.4.5. Vietnam
    • 5.4.6. South Korea
    • 5.4.7. Indonesia
    • 5.4.8. Philippines
  • 5.5. Middle East & Africa
    • 5.5.1. Saudi Arabia
    • 5.5.2. UAE
    • 5.5.3. South Africa

6. Market Mapping, 2023

  • 6.1. By Drugs
  • 6.2. By Route of Administration
  • 6.3. By Indication
  • 6.4. By End-user
  • 6.5. By Region

7. Macro Environment and Industry Structure

  • 7.1. Supply Demand Analysis
  • 7.2. Import Export Analysis
  • 7.3. Value Chain Analysis
  • 7.4. PESTEL Analysis
    • 7.4.1. Political Factors
    • 7.4.2. Economic System
    • 7.4.3. Social Implications
    • 7.4.4. Technological Advancements
    • 7.4.5. Environmental Impacts
    • 7.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 7.5. Porter's Five Forces Analysis
    • 7.5.1. Supplier Power
    • 7.5.2. Buyer Power
    • 7.5.3. Substitution Threat
    • 7.5.4. Threat from New Entrant
    • 7.5.5. Competitive Rivalry

8. Market Dynamics

  • 8.1. Growth Drivers
  • 8.2. Growth Inhibitors (Challenges and Restraints)

9. Regulatory Framework and Innovation

  • 9.1. Clinical Trials
  • 9.2. Patent Landscape
  • 9.3. Regulatory Approvals
  • 9.4. Innovations/Emerging Technologies

10. Key Players Landscape

  • 10.1. Competition Matrix of Top Five Market Leaders
  • 10.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2023)
  • 10.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 10.4. SWOT Analysis (For Five Market Players)
  • 10.5. Patent Analysis (If Applicable)

11. Pricing Analysis

12. Case Studies

13. Key Players Outlook

  • 13.1. Novartis AG
    • 13.1.1. Company Details
    • 13.1.2. Key Management Personnel
    • 13.1.3. Products & Services
    • 13.1.4. Financials (As reported)
    • 13.1.5. Key Market Focus & Geographical Presence
    • 13.1.6. Recent Developments
  • 13.2. Pfizer Inc.
  • 13.3. AstraZeneca Plc.
  • 13.4. Sanofi Winthrop Industries
  • 13.5. Boehringer Ingelheim International GmbH
  • 13.6. Merck & Co., Inc.
  • 13.7. Lupin Pharmaceutical, Inc.
  • 13.8. Sun Pharmaceutical Industries Limited
  • 13.9. Bayer AG
  • 13.10. Cipla Limited
  • 13.11. AbbVie Inc.
  • 13.12. Bristol-Myers Squibb Pharmaceuticals Limited

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work

14. Strategic Recommendations

15. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 2. Global ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 3. Global ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 4. Global ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 5. Global ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 6. Global ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 7. Global ACE Inhibitors Market Share (%), By Region, 2017-2031F
  • Figure 8. North America ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 9. North America ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 10. North America ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 11. North America ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 12. North America ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 13. North America ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 14. North America ACE Inhibitors Market Share (%), By Country, 2017-2031F
  • Figure 15. United States ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 16. United States ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 17. United States ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 18. United States ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 19. United States ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 20. United States ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 21. Canada ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 22. Canada ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 23. Canada ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 24. Canada ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 25. Canada ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 26. Canada ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 27. Mexico ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 28. Mexico ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 29. Mexico ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 30. Mexico ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 31. Mexico ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 32. Mexico ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 33. Europe ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 34. Europe ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 35. Europe ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 36. Europe ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 37. Europe ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 38. Europe ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 39. Europe ACE Inhibitors Market Share (%), By Country, 2017-2031F
  • Figure 40. Germany ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 41. Germany ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 42. Germany ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 43. Germany ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 44. Germany ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 45. Germany ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 46. France ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 47. France ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 48. France ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 49. France ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 50. France ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 51. France ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 52. Italy ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 53. Italy ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 54. Italy ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 55. Italy ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 56. Italy ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 57. Italy ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 58. United Kingdom ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 59. United Kingdom ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 60. United Kingdom ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 61. United Kingdom ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 62. United Kingdom ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 63. United Kingdom ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 64. Russia ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 65. Russia ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 66. Russia ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 67. Russia ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 68. Russia ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 69. Russia ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 70. Netherlands ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 71. Netherlands ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 72. Netherlands ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 73. Netherlands ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 74. Netherlands ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 75. Netherlands ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 76. Spain ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 77. Spain ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 78. Spain ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 79. Spain ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 80. Spain ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 81. Spain ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 82. Turkey ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 83. Turkey ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 84. Turkey ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 85. Turkey ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 86. Turkey ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 87. Turkey ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 88. Poland ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 89. Poland ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 90. Poland ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 91. Poland ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 92. Poland ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 93. Poland ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 94. South America ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 95. South America ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 96. South America ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 97. South America ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 98. South America ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 99. South America ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 100. South America ACE Inhibitors Market Share (%), By Country, 2017-2031F
  • Figure 101. Brazil ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 102. Brazil ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 103. Brazil ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 104. Brazil ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 105. Brazil ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 106. Brazil ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 107. Argentina ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 108. Argentina ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 109. Argentina ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 110. Argentina ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 111. Argentina ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 112. Argentina ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 113. Asia-Pacific ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 114. Asia-Pacific ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 115. Asia-Pacific ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 116. Asia-Pacific ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 117. Asia-Pacific ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 118. Asia-Pacific ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 119. Asia-Pacific ACE Inhibitors Market Share (%), By Country, 2017-2031F
  • Figure 120. India ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 121. India ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 122. India ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 123. India ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 124. India ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 125. India ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 126. China ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 127. China ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 128. China ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 129. China ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 130. China ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 131. China ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 132. Japan ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 133. Japan ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 134. Japan ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 135. Japan ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 136. Japan ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 137. Japan ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 138. Australia ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 139. Australia ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 140. Australia ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 141. Australia ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 142. Australia ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 143. Australia ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 144. Vietnam ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 145. Vietnam ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 146. Vietnam ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 147. Vietnam ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 148. Vietnam ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 149. Vietnam ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 150. South Korea ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 151. South Korea ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 152. South Korea ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 153. South Korea ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 154. South Korea ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 155. South Korea ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 156. Indonesia ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 157. Indonesia ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 158. Indonesia ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 159. Indonesia ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 160. Indonesia ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 161. Indonesia ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 162. Philippines ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 163. Philippines ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 164. Philippines ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 165. Philippines ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 166. Philippines ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 167. Philippines ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 168. Middle East & Africa ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 169. Middle East & Africa ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 170. Middle East & Africa ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 171. Middle East & Africa ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 172. Middle East & Africa ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 173. Middle East & Africa ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 174. Middle East & Africa ACE Inhibitors Market Share (%), By Country, 2017-2031F
  • Figure 175. Saudi Arabia ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 176. Saudi Arabia ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 177. Saudi Arabia ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 178. Saudi Arabia ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 179. Saudi Arabia ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 180. Saudi Arabia ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 181. UAE ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 182. UAE ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 183. UAE ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 184. UAE ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 185. UAE ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 186. UAE ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 187. South Africa ACE Inhibitors Market, By Value, In USD Billion, 2017-2031F
  • Figure 188. South Africa ACE Inhibitors Market, By Volume, In Million Units, 2017-2031F
  • Figure 189. South Africa ACE Inhibitors Market Share (%), By Drugs, 2017-2031F
  • Figure 190. South Africa ACE Inhibitors Market Share (%), By Route of Administration, 2017-2031F
  • Figure 191. South Africa ACE Inhibitors Market Share (%), By Indication, 2017-2031F
  • Figure 192. South Africa ACE Inhibitors Market Share (%), By End-user, 2017-2031F
  • Figure 193. By Drugs Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 194. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 195. By Indication Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 196. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023
  • Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023